CDK4 and cholangiocarcinoma: In agreement with this, several early studies using CCA and PDAC models documented that the co-administration of CDK4/6 inhibitors antagonized the therapeutic effects of various classes of chemotherapeutic compounds, such as taxanes and cisplatin [92,94].